Literature DB >> 15706445

Effects of irradiation combined with cis-diamminedichloroplatinum (CDDP) suppository in rabbit VX2 rectal tumors.

Kazuo Wakatsuki1, Kenji Oda, Keiji Koda, Kazuhiro Seike, Nobuhiro Takiguchi, Norio Saito, Masaru Miyazaki.   

Abstract

To decrease local recurrence and increase disease free survival, various preoperative therapies for patients with advanced rectal cancer have been studied. Cis-diamminedichloroplatinum (II) (CDDP) has become one of the most widely used cancer chemotherapeutic drugs. It has also been found to have radiosensitizing properties. In this experimental study, the efficacy of chemoradiotherapy using a novel CDDP suppository, and one with mixed micelles, was examined in a rabbit VX2 rectal tumor model. Rabbits were divided into four groups: control group, irradiation (R) group, CDDP suppository plus irradiation (CR) group, and mixed micelles plus CDDP suppository plus irradiation (CMR) group. Tumor growth ratios were reduced significantly in the CR and CMR groups as compared with the ratio in the control group. Microscopically, response rates of main tumors were 0%, 33.3%, 70.0%, and 91. 7%, respectively. The number of metastatic lymph nodes in the CR and CMR groups decreased significantly compared to the control group and the R group. The microscopic response rates of metastatic lymph nodes were 0%, 11.1%, 40.0%, and 41.7%, respectively. Lung metastases were observed in three rabbits in the R group, and in one rabbit in the CMR group. Tissue platinum concentrations both in tumors and in regional lymph nodes increased significantly when mixed micelles were used. Chemoradiotherapy using the CDDP suppository and mixed micelles was effective for local control in the rabbit VX2 rectal tumor model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706445     DOI: 10.1007/s00268-004-7625-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  20 in total

1.  Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer.

Authors:  V K Mehta; J Poen; J Ford; P S Edelstein; M Vierra; A J Bastidas; H Young; G Fisher
Journal:  Dis Colon Rectum       Date:  2001-01       Impact factor: 4.585

2.  Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy.

Authors:  B D Minsky; A M Cohen; N Kemeny; W E Enker; D P Kelsen; B Reichman; L Saltz; E R Sigurdson; J Frankel
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

3.  The interaction of trans-DDP [PtCl2(NH3)2] with low doses of radiation in mammalian cells.

Authors:  K A Skov; M Korbelik; B Palcic
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

Review 4.  Characteristics of drug absorption via the rectal route.

Authors:  S Muranishi
Journal:  Methods Find Exp Clin Pharmacol       Date:  1984-12

5.  Prognostic factors in patients with locally advanced rectal adenocarcinoma treated with preoperative radiotherapy and surgery.

Authors:  P Luna-Pérez; B Trejo-Valdivia; S Labastida; S García-Alvarado; D F Rodríguez; S Delgado
Journal:  World J Surg       Date:  1999-10       Impact factor: 3.352

6.  Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.

Authors:  S Boulis-Wassif; A Gerard; J Loygue; D Camelot; M Buyse; N Duez
Journal:  Cancer       Date:  1984-05-01       Impact factor: 6.860

7.  Local treatment of rabbit VX2 rectal carcinoma with combined hyperthermia and intratumoral CDDP injection.

Authors:  T Nishiue; O Kojima
Journal:  Int J Hyperthermia       Date:  1994 Sep-Oct       Impact factor: 3.914

8.  Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity.

Authors:  C R Shumate; T A Rich; J M Skibber; J A Ajani; D M Ota
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

9.  Cisplatin suppository: preparation, release characteristics and clinical evaluation.

Authors:  Y Nishioka; S Kyotani; M Kusunose; H Mimoto; T Hamada; M Asai; Y Sagara
Journal:  Chem Pharm Bull (Tokyo)       Date:  1991-06       Impact factor: 1.645

10.  Concurrent irradiation and intratumoral chemotherapy with cisplatin: a pilot study in dogs with spontaneous tumors.

Authors:  A P Théon; B R Madewell; J Ryu; J Castro
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-07-30       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.